Literature DB >> 18597053

Epstein-Barr virus-associated T-cell lymphoma in an adult patient: prominent infiltrates within the liver portal area revealed by autopsy.

Hitoshi Ohno1, Norikazu Nagata2, Kotaro Isoda3.   

Abstract

We herein report the case of a 67-year-old man who initially presented with fever and hepatosplenomegaly, and soon died of progressive liver failure. The bone marrow was infiltrated with tumor cells showing a variable morphology and macrophages phagocytosing blood cells. The tumor cells were CD2(+), CD3(+), CD4(-), CD8(+), CD25(+), CD56(+/-), and HLA-DR(+) and exhibited clonal cytogenetic abnormalities. Microscopic examination of the liver postmortem revealed, prominent cellular infiltrates that were confined within the portal area. The infiltrated cells were medium-sized with the CD3(+), CD4(-), CD8(+), CD56(+/-), and granzyme B(+) phenotype. In situ hybridization detected Epstein-Barr virus (EBV)-encoded RNA-positive cells in the liver and spleen as well as the bone marrow obtained before his death. These observations indicate that EBV-associated T-cell lymphoma expressing cytotoxic proteins was the underlying disorder. Prominent portal involvement was most likely responsible for the fatal clinical outcome of this patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18597053     DOI: 10.1007/s12185-008-0122-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.

Authors:  H Kimura; Y Hoshino; H Kanegane; I Tsuge; T Okamura; K Kawa; T Morishima
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

2.  Peripheral T-cell lymphoma associated with hemophagocytic syndrome.

Authors:  B Falini; S Pileri; I De Solas; M F Martelli; D Y Mason; G Delsol; K C Gatter; M Fagioli
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113

3.  Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis.

Authors:  A Ost; S Nilsson-Ardnor; J I Henter
Journal:  Histopathology       Date:  1998-04       Impact factor: 5.087

4.  Peripheral T-cell lymphoma associated with hemophagocytic syndrome and hemophagocytic lymphohistiocytosis of children: do they share something?

Authors:  M Aricò
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

5.  Clonal karyotype abnormalities in EBV-associated hemophagocytic syndrome.

Authors:  J S Chen; C C Tzeng; C J Tsao; W C Su; T Y Chen; Y C Jung; I J Su
Journal:  Haematologica       Date:  1997 Sep-Oct       Impact factor: 9.941

6.  Hepatosplenic gammadelta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules.

Authors:  K Ohshima; S Haraoka; N Harada; T Kamimura; J Suzumiya; M Kanda; C Kawasaki; M Sugihara; M Kikuchi
Journal:  Histopathology       Date:  2000-02       Impact factor: 5.087

Review 7.  Pathobiology of peripheral T-cell lymphomas.

Authors:  Elaine S Jaffe
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

8.  Hemophagocytic lymphohistiocytosis in children: abdominal US findings within 1 week of presentation.

Authors:  Matthias H Schmidt; Lillian Sung; Bruce M Shuckett
Journal:  Radiology       Date:  2004-03       Impact factor: 11.105

9.  Clonal and non-clonal karyotypically abnormal cells in haemophagocytic lymphohistiocytosis.

Authors:  Y Kaneko; N Maseki; M Sakurai; M Ido; Y Tsunematsu; S Mizutani; T Hattori; H Shimizu; H Eguchi; T Oka
Journal:  Br J Haematol       Date:  1995-05       Impact factor: 6.998

Review 10.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.